Cell Therapeutics said it hit its treatment goals in a trial of pixantrone in patients with relapsed non-Hodgkin's lymphoma, but investors...
Cell Therapeutics said it hit its treatment goals in a trial of pixantrone in patients with relapsed non-Hodgkin’s lymphoma, but investors sold off the Seattle company’s stock anyhow.
The 38-patient late-stage clinical trial compared pixantrone in combination with Rituxan — the first monoclonal antibody approved in the U.S. for treating cancer — to Rituxan alone. Patients who received the combination treatment went an average of 13.2 months without the cancer advancing, while in patients taking just Rituxan the disease progressed in 8.1 months.
Also, three-quarters of patients on the combined treatment saw the size of their tumors reduced by half or more, compared to one-third of patients in the other group.
One issue for the company: The study succeeded in recruiting only 5 percent of the patients it had sought.
Most Read Stories
- What you need to know about Inauguration Day protests, events in Seattle
- 50,000 expected to attend Seattle women’s march day after Trump inauguration WATCH
- Live updates from Inauguration Day: 1 injured in shooting at demonstration at UW, shooter at large WATCH
- Christopher Monfort, killer of Seattle police officer, found dead in prison cell
- Police seek description of shooter who wounded 3 at Seattle’s Crocodile club
Designed to enroll 728 patients, the Phase III trial was closed in 2004 due to difficulty meeting that target. Investigators still had statistically significant results, the company said, despite the small patient population.
The company’s stock fell 26 cents, or 9.6 percent, Wednesday after the results were announced, and dropped another 2 cents Thursday, closing at $2.43.